Safety Monitoring

Determination of 11 related substances in flurbiprofen axetil injection by HPLC*

  • WANG Xue ,
  • ZHANG Xiao-han ,
  • LI Tie-jun ,
  • LI Wen-xin ,
  • LI Lin ,
  • YANG Shu-juan ,
  • ZHANG Lian-yi ,
  • DOU Yan-li ,
  • GUO Chang-chuan ,
  • XU Yu-wen
Expand
  • 1. Shandong Institute for Food and Drug Control, National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Generic Drugs, Shandong Research Center of Engineering and Technology for Consistency Evaluation of Generic Drugs, Industrial Technology Foundation Public Service Platform, Jinan 250101, China;
    2. Shandong Institute of Medical Device and Pharmaceutical Packaging Inspection, Jinan 250101, China;
    3. Jewim Pharmaceutical (Shandong) Co., Ltd., Taian 271000, China);

Received date: 2024-07-29

  Online published: 2025-08-25

Abstract

Objective: To establish a principal component external standard method with HPLC and calibration factors for the determination of 11 impurities in flurbiprofen axetil injection, and to explore its detection results and limit values. Methods: The Thermo BDS Hypersil C18 (250×4.6 mm, 5 μm) was selected for gradient elution, with water-0.15% acetic acid and acetonitrile-0.15% acetic acid as the mobile phase at a flow rate of 1.0 mL · min-1.The column temperature was 40 ℃, the detection wavelength was 254 nm and the injection volume was 10 μL.Results: Flurbiprofen axetil and 11 impurities were well separated by the method. Good linearity was obtained with correlation coefficients of 1.000 for the 3-fluoro-4-phenylphenol (4-OHB), 1-acetoxyethyl-2-(2-fluoro-4-biphenylyl)-2-hydroxypropionate (2-OHP), 4-acetyl-2-fluorobiphenyl (4-ACB), flurbiprofen ethyl ester, allyl - (2-fluoro-4-biphenyl) propionate (ALE), ChP impurity Ⅰ, impurity B, impurity C and impurity E in the range of 0.10-20 μg · mL-1. The average recovery rates was from 96.6% to 103.7% and the relative standard deviations (RSDs) were lower than 1.4%. The correction factors of flurbiprofen axetil related substances 4-OHB, 2-OHP, 4-ACB, flurbiprofen, flurbiprofen ethyl ester, ALE, ChP impurity Ⅰ, impurity B, impurity C and impurity E were 0.55, 1.05, 1.01, 0.76, 0.95, 0.86, 0.55, 0.93, 0.76 and 0.81, respectively. Notablely, desfluoro fiurbiprofen axetil of detected was around the prescribed limit 0.1%. Conclusion: The method above is rapid, simple, accurate, and reliable, and can be applied for the determination and quality control of related substances in flurbiprofen axetil injection.

Cite this article

WANG Xue , ZHANG Xiao-han , LI Tie-jun , LI Wen-xin , LI Lin , YANG Shu-juan , ZHANG Lian-yi , DOU Yan-li , GUO Chang-chuan , XU Yu-wen . Determination of 11 related substances in flurbiprofen axetil injection by HPLC*[J]. Chinese Journal of Pharmaceutical Analysis, 2025 , 45(2) : 246 -253 . DOI: 10.16155/j.0254-1793.2024-0489

References

[1] HAO J,WANG K,SHAO Y,et al.Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain:a clinical study[J].J Palliat Med,2013,16(2):190
[2] 王天兵,姜保国,杨惠林,等.氟比洛芬巴布膏治疗骨科急慢性疼痛的多中心临床研究[J].中日友好医院学报,2013,27(1):18
WANG TB,JIANG BG,YANG HL,et al.Multicentre clinical research on flurbiprofen cataplasm for treating acute and chronic pain[J].J China Japan Friendship Hosp,2013,27(1):18
[3] 王统杰. 氟比洛芬巴布膏治疗急性软组织损伤的临床观察[J].中国医学工程,2013,21(6):37
WANG TJ.Clinical observation of flurbiprofen Babu ointment in the treatment of acute soft tissue injury[J].Chin Med Eng,2013,21(6):37
[4] 章秀丽,马月琴,李刚.脂微球载药系统的研究进展[J].药学实践杂志,2014,32(6):409
ZHANG XL,MA YQ,LI G,et al.Research development of lipid microsphere delivery system[J].J Pharm Pract,2014,32(6):409
[5] 吴燕,李冬梅,徐超斗,等.氟比洛芬酯脂微球注射液的制备及其质量评价[J].中国药学杂志,2013,48(21):1847
WU Y,LI DM,XU CD,et al.The preparation and evaluation of flurbiprofen axetil lipid microsphere injection[J].Chin Pharm J,2013,48(21):1847
[6] YAMASHITA K,FUKUSAKI M,ANDO Y,et al.Preoperative administration of intravenous flurbiprofen axetil reduces postoperative pain for spinal fusion surgery[J].J Anesth,2006,20(2):92
[7] 林赳杨. 氟比洛芬酯注射液的术后镇痛效果分析[J].现代诊断与治疗,2012,23(2):2
LIN JY.Analgesic effect and safety evaluation of flurbiprofen axetil injection in abdominal surgery[J].Pract J Clin Med,2012,23(2):2
[8] WANG RD,SHENG XR,GUAN WX,et al.Flurbiprofen axetil for postoperative analgesia in upper abdominal surgery:a randomized,parallel controlled,double-blind,multicenter clinical study[J].Surg Today,2020.doi:10.1007/s00595-019-01951-1
[9] XU Y,TAN Z,CHEN J,et al.Intravenous flurbiprofen axetil accelerates restoration of bowel function after colorectal surgery[J].Can J Anesth,2008,55(7):414
[10] 戴杰,高云睿,梁中卫,等.HPLC法测定氟比洛芬酯注射液的含量和有关物质[J].山东化工,2021,50(20):103
DAI J,GAO YR,LIANG ZW,et al.HPLC simultaneous determination of flurbiprofen axetil and related substance from flurbiprofen axetil injection[J].Shandong Chem,2021,50(20):103
[11] 黄丽,魏龙,李何美,等.58例氟比洛芬不良反应文献分析[J].中国药物警戒,2022,19(4):436
HUANG L,WEI L,LI HM,et al.Literature review of 58 cases of adverse drug reactions induced by flurbiprofen[J].Chin J Pharmacov,2022,19(4):436
[12] 谢菡,陈思煌,陈大宇,等.不同厂家氟比洛芬酯注射液有效性和安全性的真实世界研究[J].医药导报,2023,42(2):193
XIE H,CHEN SH,CHEN DY,et al.Comparison of efficacy and safety between flurbiprofen axetil injections from two manufacturers:a real world study[J].Her Med,2023,42(2):193
[13] YBH15412004-2014Z氟比洛芬酯注射液.国家食品药品监督管理总局药品标准[S].2014
YBH15412004-2014Z Flurbiprofen axetil injection.National Standards of the People’s Republic of China[S].2014
[14] YBH00382018氟比洛芬酯注射液.国家食品药品监督管理总局药品标准[S].2018
YBH00382018 Flurbiprofen Axetil Injection.Standard of China Food and Drug Administration[S].2018
[15] 程栎,郑瑞峥,周丽莹,等.一种氟比洛芬酯药品中有关杂质的检测方法:中国,CN202011080757.8[P].2024-07-28
CHENG L,ZHENG RZ,ZHOU LY,et al.A Detection Method for Impurities in a Flurbiprofen Ester Drug:China,CN202011080757.8[P].2024-07-28
[16] 中华人民共和国药典2020年版.二部[S].2020:913
ChP 2020.Vol Ⅱ[S].2020:913
[17] EP 11.0.Vol ⅡP 11.0.Vol Ⅱ[S]. 2023:2815
[18] 俞伟,尹超,颜国明.氟比洛芬酯的合成进展[J].广东化工,2020,47(6):3
XU W,YIN C,YAN GM.Progress in the synthesis of flurbiprofen[J].Gongdong Chem,2020,47(6):3
Outlines

/